Adjuvant treatment of parkinson's disease with dopamine agonists: Open trial with bromocriptine and CU 32-085

@article{Jellinger1982AdjuvantTO,
  title={Adjuvant treatment of parkinson's disease with dopamine agonists: Open trial with bromocriptine and CU 32-085},
  author={Kurt Jellinger},
  journal={Journal of Neurology},
  year={1982},
  volume={227},
  pages={75-88}
}
Bromocriptine (CB-154) and the 8-α-ergoline CU 32-085, two dopamine receptor agonists, were administered at different times to two series of 22 patients with Parkinson's disease, most of whom took levodopa (plus benserazide) at optimum dosage. The addition of bromocriptine (mean daily dose 32 mg; after 6 months 40 mg) led to a 38.5% reduction of levodopa, while CU 32-085 (mean daily dose 15.2 mg; after 6 months 17.5 mg) permitted a 33.7% reduction in levodopa. The mean dose in two patients on… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Pharmacology of CU 32-085

  • E FlJckinger
  • 1980
Highly Influential
5 Excerpts

Die Parkinson-Krankheit

  • W Birkmayer, P Riederer
  • 1980
Highly Influential
4 Excerpts

Parkinson-Syndrom: Kombinations- und Begleittherapien

  • Fischer P-A
  • F.K. Schattauer,
  • 1980
Highly Influential
6 Excerpts

Bromocriptine and lergotrile: Comparative efficacy in Parkinson disease

  • AN Lieberman, M Kupersmith, +5 authors M Goldstein
  • Poirier L J, Sourkes TL, B~dard PJ (eds) Advances…
  • 1979
Highly Influential
5 Excerpts

Isgreen WP (1979)The role of bromocriptine in the treatment of parkinsonism. Neurology (Minneap) 29:1077-1083 Treatment of Parkinson's Disease with Dopamine Agonists

  • Fahn St, J CoteL, Snider StR, RE Barrett
  • 1979
Highly Influential
8 Excerpts

Similar Papers

Loading similar papers…